Hepatologist Tim Jobson, co-founder of Predictive Health Intelligence, joins Louise Campbell and Roger Green to provide an update on PHI’s work and discuss implications for databases, patient recruitment and special population issues.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
Fatty Liver Alliance Founder Mike Betel joins Roger Green to consider how patient incentives to participate in MASH clinical trials might need to change now that prescribers have an approved drug for treating MASH patients.
MASLD patient advocates consider new needs and opportunities for other stakeholders after the Rezdiffra approval and launch.
MASLD patient advocates consider the impact Rezdiffra approval and accompanying promotion and education might have on the U.S. healthcare system.
Patient advocates, led by GLI’s Jeff McIntyre, discuss advocates’ goals for a MASH drug label and the steps they took to communicate this information to FDA.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
The conversation on Rezdiffra, the first MASH drug, wraps up with the panelists answering a inviation to discuss any other issues of interest that had not arisen in the conversation.
This conversation includes two separate themes: the rationale and impact around the price of resmetirom, and the impact of GLP-1s on resmetirom use in patients with MASH.
This conversation focuses on why it will be challenging to use currently-available NITs to stage patients with advanced MASH fibrosis (F2/F3) accurately with current test options.
